Company / PP&E (Net)
Amphstar Pharmaceuticals, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$310.6M
FY2025
5-year range
$238.3M / $310.6M
FY2021-FY2025
Trend
+4.4%
vs FY2024
Sector context
#26 of 193
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s pp&e (net) of $311M is higher than 87% of companies in the Health Care sector (FY2025). PP&E (Net) has increased for 3 consecutive years, from $238M in FY2022 to $311M in FY2025.
Based on SEC 10-K filings.
$311M in FY2025 with a 5-year CAGR of +3.6%. Top quartile in the Health Care sector.
Improved from $283M to $311M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +9.2%
- 5-Year CAGR
- +3.6%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 193This company $310.6M Sector average $777.6M
▼
-60.1% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of +3.6%, indicating consistent growth.
- In FY2025, pp&e (net) increased 4.4% year-over-year.
- Ranks #26 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $310.6M | +4.4% |
| FY2024 | $297.3M | +5.2% |
| FY2023 | $282.7M | +18.7% |
| FY2022 | $238.3M | -2.4% |
| FY2021 | $244.2M | -6.1% |
| FY2020 | $260.1M | +11.2% |
| FY2019 | $233.9M | +11.1% |
| FY2018 | $210.4M | +16.5% |
| FY2017 | $180.5M | +18.0% |
| FY2016 | $152.9M | +7.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026